Definition
Cancer-related morbidity and mortality from prostate cancer are destined to remain a significant public health burden in the coming decade. While testosterone-reducing strategies remain the cornerstone of treating advanced prostate cancer, progression of disease is inevitable to castration recurrence stages. Recent advances have focused on the recognition that androgen receptor functioning remains strong despite the paucity of circulating androgens due to traditional testosterone-reducing interventions. This has resulted in the development of novel hormonal compounds targeting castration-resistant prostate cancer.
Characteristics
Epidemiology
A global epidemic of cancer is projected in the next decade with a rise in cancer incidence from 12.9 million new cases worldwide in 2009 to 16.8 million in 2020. In 2009 worldwide the most common tumor types observed are lung cancer (12.6 %), breast cancer (10.5 %), colorectal cancer (9.4 %), gastric cancer (8.7 %), and prostate cancer...
This is a preview of subscription content, log in via an institution to check access.
References
Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 355(9214):1491–1498. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10801170
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362(13):1192–1202. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20357281
Attard G, Reid AH, A’Hern R, Parker C, Oommen NB, Folkerd E et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19470933
Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16983113
Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19359544
Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT (2008) Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 54(4):805–813. Available from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18538469
See Also
(2012) 5-alpha reductase. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 147–148. doi: 10.1007/978-3-642-16483-5_6815
(2012) Cell cycle. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 737. doi: 10.1007/978-3-642-16483-5_994
(2012) Dihydrotestosterone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1117. doi: 10.1007/978-3-642-16483-5_6813
(2012) Dutasteride. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1171. doi: 10.1007/978-3-642-16483-5_6814
(2012) Finasteride. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1407. doi: 10.1007/978-3-642-16483-5_2191
(2012) Follicle-stimulating hormone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1441. doi: 10.1007/978-3-642-16483-5_2235
(2012) GnRH analogs. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 1576. doi: 10.1007/978-3-642-16483-5_2471
(2012) LHRH. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 2033–2034. doi: 10.1007/978-3-642-16483-5_3342
(2012) LHRH antagonists. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2034. doi: 10.1007/978-3-642-16483-5_6837
(2012) Luteinizing hormone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 2115–2116. doi: 10.1007/978-3-642-16483-5_6804
(2012) Orchiectomy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 2654–2655. doi: 10.1007/978-3-642-16483-5_4251
(2012) PSA. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, pp 3111–3112. doi: 10.1007/978-3-642-16483-5_6738
(2012) Prodrug. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2989. doi: 10.1007/978-3-642-16483-5_4751
(2012) Testosterone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3660. doi: 10.1007/978-3-642-16483-5_5741
(2012) Transcription. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3752. doi: 10.1007/978-3-642-16483-5_5899
(2012) Transcription factor. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3752. doi: 10.1007/978-3-642-16483-5_5901
(2012) Tumor flare. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3795. doi: 10.1007/978-3-642-16483-5_6836
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Kohli, M., Tindall, D.J. (2014). Prostate Cancer Hormonal Therapy. In: Schwab, M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27841-9_6830-5
Download citation
DOI: https://doi.org/10.1007/978-3-642-27841-9_6830-5
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Online ISBN: 978-3-642-27841-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences